Profile for Costa Rica Patent: 20150467

US Patent Family Members and Approved Drugs for Costa Rica Patent: 20150467

The international patent data are derived from patent families, based on US drug-patent linkages. Full freedom-to-operate should be independently confirmed.

US Patent Number	US Expiration Date	US Applicant	US Tradename	Generic Name
	Nov 21, 2034	Novartis Pharms Corp	JADENU	deferasirox

Detailed Analysis of the Scope, Claims, and Patent Landscape for Costa Rica Patent CR20150467

---

Introduction

Patent CR20150467, filed and granted within Costa Rica, pertains to a novel pharmaceutical invention. An in-depth understanding of its scope, claims, and placement within the broader patent landscape is essential for stakeholders including patent holders, competitors, licensors, and regulators. This analysis provides a comprehensive examination of the patent's legal claims, technological scope, and the regional and global patent environment, offering insights into enforceability, innovation scope, and strategic positioning.

---

Patent Overview and Basic Facts

CR20150467 was filed earlier in the patent application process in Costa Rica, with official grant details indicating its issuance around 2015. While operational data on filing dates and priority claims are not explicitly provided here, the patent likely claims a pharmaceutical composition or process related to a specific drug molecule or formulation, considering typical drug patent categories.

Patent documents in Costa Rica are regulated under Ley de Patentes (Patent Law), aligned with the Andean Community Patent Legislation, emphasizing patentability criteria such as novelty, inventive step, and industrial applicability.

---

Scope of the Patent Claims

Claims Analysis:

The core of any patent’s legal strength lies in its claims, which define the invention's legal boundaries. CR20150467's claims, potentially linguistic proxies for its protective scope, generally fall into two categories: independent and dependent claims.

• Independent Claims:
  These likely define the broadest scope, possibly covering the chemical compound, composition comprising this compound, or a method of manufacturing or therapeutic use. For instance, an independent claim may specify a novel molecule with a particular structure, such as a specific chemical formula or a unique stereochemistry.

• Dependent Claims:
  These narrow the scope, attaching specific features or embodiments, such as particular formulations, concentrations, excipients, or dosing regimens, to the core invention.

Key Elements Likely Covered:

• Novel Chemical Entity:
  If the patent claims a new molecule or a novel chemical modification, its scope hinges upon the structural definition, including substituents, stereochemistry, and functional groups.

• Pharmaceutical Formulation:
  Claims might extend to specific formulations, including sustained-release matrices, combinations, or drug delivery systems.

• Manufacturing Process:
  Methods of synthesis or preparation that lead to the claimed compound could be part of the scope if specifically claimed.

• Therapeutic Use:
  Claims may encompass methods of treatment using the compound or formulations, provided such use is novel and non-obvious.

Claim Language and Limitations:

Given typical patent drafting practices, the claims are likely precise but potentially broad to cover variants, drawing a balance to avoid invalidation through prior art. The scope may include chemical structures, intermediate compounds, and methods, all framed within the novelty and inventive steps.

---

Patent Landscape and Regional Context

Costa Rican Patent Environment:

Costa Rica’s patent regime aligns with regional standards similar to those set by the Central American region and the Patent Cooperation Treaty (PCT). The country's patent office, the Dirección de Propiedad Intelectual (DIGEPATI), examines patents for novelty, inventive step, and industrial applicability. Costa Rican patent law offers 20 years of protection from filing date, similar to international standards, with no utility models or supplementary protection certificates explicitly mentioned for pharmaceutical patents.

Regional and International Patent Strategy:

• Latin American Patents:
  Given Costa Rica's participation in regional treaties like ARIPO and OAPI, strategic patent filings are often pursued across multiple jurisdictions to maximize regional protection.

• Global Patent Landscape:
  If the invention claims a novel chemical entity, securing patents in major markets such as the US (via USPTO), European Union (EPO), and China is essential. Such filings would typically involve PCT applications, which can eventually enter national phases in respective jurisdictions.

• Patent Family and Priority:
  The origin of CR20150467’s claims likely stems from an earlier priority filing, possibly a PCT application, solidifying the invention's international protections.

---

Analysis of Special Considerations

• Patentability and Validity Risks:
  To enforce or license effectively, the patent must withstand validity challenges, especially if similar compounds or formulations exist. Prior art searches in scientific literature, patent databases (e.g., Espacenet, WIPO PATENTSCOPE, USPTO), and regional patent records should confirm the claims' novelty.

• Potential for Patent Infringement and Enforcement:
  Considering the geographic scope—limited to Costa Rica unless extended—competitors may attempt to design around the patent, such as modifying compound structures or delivery methods non-infringing on claims.

• Remaining Patent Life and Market Exclusivity:
  With a 2015 grant, the patent’s expiry date around 2035 offers approximately 12 operational years for market exclusivity, incentivizing continued R&D investments or licensing negotiations.

Strategic Implications

• For Patent Holders:
  CR20150467 can serve as leverage for licensing or settlements within Costa Rica and possibly as part of a broader patent portfolio covering Latin American markets.

• For Competitors:
  Dissection of the claims to determine design-around options and patent invalidation strategies is paramount. They should investigate prior art references to challenge validity, especially if the claims are broad.

• For Regulators:
  Ensuring the patent complies with national laws and does not hinder access to essential medicines is crucial, considering the socio-economic context of Costa Rica familiar with public health priorities.

---

Conclusion

CR20150467 represents a strategically significant patent within Costa Rica’s pharmaceutical patent landscape, typically characterized by claims that aim to broadly protect a novel compound or formulation. Its scope likely encompasses chemical structures, manufacturing processes, and therapeutic uses, with the potential for regional and international extension. Vigilant monitoring of prior art, diligent management of patent rights, and strategic positioning against potential infringers are vital to maximizing the patent’s commercial and legal value.

---

Key Takeaways

• Broader claims enhance protection, but require careful drafting to withstand prior art challenges.
• Regional patent strategies should involve securing patents in major markets via PCT filings, complemented by Costa Rican protections.
• Rampant patent enforcement or licensing is feasible within Costa Rica’s enforcement framework, provided validity is maintained through robust prosecution and strategic patent landscape analysis.
• Monitoring and analyzing prior art are essential to prevent invalidation and to develop effective countermoves for competitors.
• Long-term patent management involves keeping abreast of legal developments, potential patent term extensions, and geographic expansion opportunities.

---

FAQs

1. What is the typical patent protection period for pharmaceuticals in Costa Rica?

   • Twenty years from the filing date, consistent with international standards under the Patent Law.

2. How can I determine if CR20150467 is valid and enforceable?

   • Conduct a validity search including prior art existing before the filing date, review for compliance with patentability criteria, and assess how comparable inventions impact scope.

3. Can similar compounds or formulations infringe on CR20150467?

   • Infringement depends on the scope defined by the patent claims; modifications outside the claims’ scope generally avoid infringement.

4. Does Costa Rica provide for patent term extensions for pharmaceuticals?

   • No, Costa Rican law does not currently recognize supplementary protection or patent term extensions; protection lasts 20 years from filing.

5. Should I pursue international patent protection for similar inventions?

   • Yes; filing via PCT and subsequently entering national phases in key jurisdictions maximizes market coverage and enforcement potential.

---

References:

Last updated: July 27, 2025

[1] Costa Rican Patent Law (Ley de Patentes), Dirección de Propiedad Intelectual (DIGEPATI).
[2] WIPO. (2022). PATENTSCOPE Database.
[3] Espacenet Patent Search.
[4] World Intellectual Property Organization. (2022). Guide to Patent Landscape Analysis.